

Gene Therapy Market to Garner \$6.21 Billion by 2026 at 34.8% CAGR

High investment in R&D activities, increase in prevalence of cancer, and growth in awareness regarding gene therapy drive the growth of the gene therapy market

PORTLAND, OR, UNITED STATES,
September 22, 2020 /
EINPresswire.com/ -- Allied Market

Research recently published a report, titled, "[Gene Therapy Market](#) by Vector Type (Viral Vector and Non-viral Vector), Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others), and Application (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases): Global Opportunity Analysis and Industry Forecast, 2019–2026". According to the report, the global gene therapy industry was pegged at \$393.35 million in 2018, and is projected to reach \$6.21 billion by 2026, registering a CAGR of 34.8% from 2019 to 2026.

Prime determinants for growing market

High investment in R&D activities, increase in prevalence of cancer, and growth in awareness regarding gene therapy have boosted the growth of the global gene therapy market. However, high costs associated with gene therapies and unwanted immune responses hamper the market growth. On the contrary, untapped potential for the emerging market is expected to create lucrative opportunities in the near future.

Request Sample Report at: <https://www.alliedmarketresearch.com/request-sample/2841>

Viral vector segment dominated the market

The viral vector segment held the largest share in 2018, contributing to more than half of the global gene therapy market, owing to easier modifications of many viruses such as Lentivirus,



Adeno-Associated Virus (AAV), RetroVirus & Gamma RetroVirus to deliver gene therapy drugs. However, the non-viral vector segment is expected to register the fastest CAGR of 38.8% during the forecast period. This is attributed to the technological advancements in physicochemical approaches such as physical methods and chemical methods of non-viral vectors.

Tumor suppressor segment to manifest fastest CAGR through 2026

The tumor suppressor segment to portray the fastest CAGR of 52.9% during the forecast period, owing to rise in number of methodology and clinical trials of tumor suppressor for the gene therapy treatment. However, the antigen segment held the largest share in 2018, contributing to more than one-fifth of the global gene therapy market, due to the presence of a wide range of genetic mutations and dysregulated gene expression of tumor cells.

North America held the lion's share

The global gene therapy market across North America held the largest share in 2018, accounting for nearly half of the market, owing to high prevalence rate of cancer, presence of high disposable income, and increase in funding for R&D activities associated with gene therapy. However, the market across the Asia-Pacific region is projected to register the fastest CAGR of 45.4% during the forecast period, owing to rise in number of people prone to various chronic diseases and approval & launch of gene therapy products.

For Purchase Enquiry at: <https://www.alliedmarketresearch.com/purchase-enquiry/2841>

Major market players

Adaptimmune Therapeutics Plc.
Achieve Life Sciences, Inc.
Anchiano Therapeutics Ltd.
Abeona Therapeutics Inc.
Adverum Biotechnologies, Inc.
Arbutus Biopharma Corporation
Applied Genetic Technologies Corporation
AveXis, Inc.
Audentes Therapeutics, Inc.
Celgene Corporation
Bluebird Bio, Inc.
Editas Medicine, Inc.
CRISPR Therapeutics AG
GlaxoSmithKline Plc.
Editas Medicine, Inc.
Merck & Co., Inc.
Intellia Therapeutics, Inc.

REGENXBIO Inc.
Novartis AG
Sangamo Therapeutics, Inc.
Spark Therapeutics, Inc.
Uniqure N. V.
Voyager Therapeutics, Inc.

Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at:
<https://www.alliedmarketresearch.com/knowledgetree>

Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.

Similar Reports:

[Healthcare Chatbots Market](#) - Global Opportunity Analysis and Industry Forecast, 2018–2026
[Antihyperlipidemic Drugs Market](#) - Global Opportunity Analysis and Industry Forecast, 2019–2026

David Correa
Allied Analytics LLP
+1 800-792-5285
[email us here](#)

Visit us on social media:

[Facebook](#)
[Twitter](#)
[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/526778342>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.